Celgene's Apremilast Encourages - Analyst Blog

By
A A A

Recently, Celgene Corporation ( CELG ) announced positive results on its candidate apremilast from a phase III study (ESTEEM 1), which evaluated patients suffering from moderate-to-severe chronic plaque psoriasis. The data was presented at the annual meeting of the American academy of dermatology. ESTEEM 1 is Celgene's first phase III study in the psoriasis indication.

The study evaluated efficacy and safety of the candidate in a range of psoriasis patients. Approximately 33 % of the study population was systemic and/or phototherapy treatment-naïve. Almost 30% of the overall study population had undergone prior biologic therapy.

Data from the study revealed that approximately 33.1% patients in the apremilast arm demonstrated a 75% reduction in their PASI (psoriasis area and severity index) score at week 16 as opposed to only 5.3% in the placebo arm. Moreover, the candidate was well tolerated in the study and was found to be safe

Celgene intends to seek US approval for apremilast in the psoriasis indication in the second half of 2013. The company is also evaluating apremilast in patients suffering from psoriatic arthritis. It intends to seek US approval for apremilast in the psoriatic arthritis indication shortly.

European approval for apremilast in the psoriasis and psoriatic arthritis indications (combined) is expected to be sought in the second half of 2013. The candidate is also undergoing phase III studies in the ankylosing spondylitis indication. The data is expected in 2014.

Celgene, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Biopharma stocks, such as Array Biopharma ( ARRY ), Celldex Therapeutics, Inc. ( CLDX ) and Kythera Biopharmaceuticals, Inc. ( KYTH ) are comparatively well placed and carry a Zacks Rank #2 (Buy).



ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report

CELGENE CORP (CELG): Free Stock Analysis Report

CELLDEX THERAPT (CLDX): Free Stock Analysis Report

KYTHERA BIOPHRM (KYTH): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: ARRY , CELG , CLDX , KYTH

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

100,376,898
  • $17.62 ▲ 0.51%
83,231,837
  • $25.62 ▲ 1.91%
75,739,329
  • $111.78 ▼ 0.77%
65,297,937
  • $36.37 ▼ 1.76%
59,053,093
  • $47.66 ▲ 0.29%
53,482,350
  • $2.59 ▼ 0.38%
51,504,284
  • $7.34 ▲ 2.37%
51,434,656
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com